Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.59 |
| ▸ | RET | P07949 | 2/20 | 0.59 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.59 |
| ▸ | MST1R | Q04912 | 1/20 | 0.59 |
| ▸ | CIT | O14578 | 1/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.54 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.54 |
| ▸ | STK17B | O94768 | 1/20 | 0.54 |
| ▸ | STK10 | O94804 | 1/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5231564 | 1.00 | EGFR (0.60) | EGFRERBB2RETERBB4MST1R | |
| SCHEMBL5226439 | 1.00 | EGFR (0.60) | EGFRERBB2RETERBB4MST1R | |
| SCHEMBL5228566 | 0.92 | EGFR (0.60) | EGFRERBB2RETERBB4MST1R | |
| SCHEMBL5225648 | 0.92 | EGFR (0.60) | EGFRERBB2RETERBB4MST1R | |
| SCHEMBL5227344 | 0.90 | EGFR (0.62) | EGFRERBB2RETERBB4CIT | |
| SCHEMBL5224316 | 0.90 | EGFR (0.62) | EGFRERBB2RETERBB4CIT | |
| SCHEMBL29623487 | 0.90 | EGFR (0.71) | EGFRERBB2RETERBB4CIT | |
| SCHEMBL175222 | 0.90 | EGFR (0.71) | EGFRERBB2RETERBB4CIT | |
| SCHEMBL5230874 | 0.90 | EGFR (0.71) | EGFRERBB2RETERBB4CIT | |
| SCHEMBL1446516 | 0.87 | EGFR (0.76) | EGFRERBB2RETERBB4MST1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315718-B1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-11-28 | — | — | EP | claimed |
| EP-1315718-B1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-11-28 | — | — | EP | disclosed |
| US-6617329-B2 | Administering a therapeutically effective amount of aminoquinozoline compound to treat benign or malignant tumour, a disease of the respiratory tract or lungs, polyps, kidney or skin disease and a disease of gastrointestinal tract | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-09 | — | — | US | disclosed |
| US-20020049197-A1 | Aminoquinazolines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049197-A1 | Aminoquinazolines and their use as medicaments | JAK1, ABL1, JAK2 | EGFR 246/4885ERBB2 41/4885RET 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.